ClinicalTrials.Veeva

Menu

Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer (PACO)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Ovarian Cancer

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage.

Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Enrollment

130 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patient (≥18 years old)
  • Operated on at the HUS between January 1, 2010 and December 31, 2022
  • Having undergone primary or interval cytoreductive surgery
  • Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin

Exclusion criteria

  • Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques.
  • Autres types histologiques de cancer de l'ovaire
  • Stades de la maladie FIGO I, II, IIIA et IIIC
  • Chirurgie de clôture.

Trial contacts and locations

1

Loading...

Central trial contact

Lise LECOINTRE, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems